Advertisement
Advertisement

TECX

TECX logo

Tectonic Therapeutic, Inc. Common Stock

23.24
USD
Sponsored
+0.30
+1.32%
Feb 04, 16:00 UTC -5
Closed
exchange

After-Market

23.22

-0.02
-0.10%

TECX Earnings Reports

Positive Surprise Ratio

TECX beat 14 of 30 last estimates.

47%

Next Report

Date of Next Report
Mar 18, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.12
Implied change from Q3 25 (Revenue/ EPS)
--
/
+9.80%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+33.33%

Tectonic Therapeutic, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, TECX reported earnings of -1.02 USD per share (EPS) for Q3 25, beating the estimate of -1.06 USD, resulting in a 4.50% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -1.12 USD, with revenue projected to reach -- USD, implying an increase of 9.80% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
logo
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
logo
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
logo
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
logo
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
For Q3 2025, Tectonic Therapeutic, Inc. Common Stock reported EPS of -$1.02, beating estimates by 4.5%, and revenue of $0.00, 0% as expectations.
The stock price moved up 1.74%, changed from $18.99 before the earnings release to $19.32 the day after.
The next earning report is scheduled for Mar 18, 2026.
Based on 9 analysts, Tectonic Therapeutic, Inc. Common Stock is expected to report EPS of -$1.12 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement